Werewolf Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 47
- Market Cap
- $99.6M
- Website
- http://www.werewolftx.com
- Introduction
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
- Conditions
- Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Werewolf Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06939283
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Conditions
- Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Werewolf Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05678998
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Emory Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Werewolf Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05479812
- Locations
- 🇺🇸
Minnesota Oncology Hematology, P.A., Maple Grove, Minnesota, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
News
Novel IL-2 Derivative Shows Complete Remission in Advanced Skin Cancer Patient After One Year
• A 73-year-old patient with advanced cutaneous squamous cell carcinoma has remained cancer-free for over a year following treatment with WTX-124, a novel conditionally activated IL-2 pro-drug, in a clinical trial at HonorHealth Research Institute. • The investigational drug is engineered to remain inactive until it reaches the tumor microenvironment, potentially delivering the benefits of IL-2 therapy with significantly reduced toxicity compared to conventional treatments. • This breakthrough offers new hope for the nearly 40,000 U.S. patients annually who develop advanced cutaneous squamous cell carcinoma, particularly those who have failed standard treatments including checkpoint inhibitor therapy.
Werewolf Therapeutics Announces 2025 Milestones for IL-2 and IL-12 INDUKINE Programs
Werewolf Therapeutics anticipates sharing preliminary monotherapy data for WTX-124 in H1 2025, potentially guiding regulatory engagement for accelerated approval.